Welcome back everyone, The stock markets are enduring some tough times right now
but its in times like this when we dig deep to pick up long term winners.
And so in this video, I have for you 1 top penny stock which is deeply undervalued
right now and not only does it change life but is looking to disrupt a $30bn industry
with considerable unmet needs by providing solutions for psychedelic medicine,
through treatments and therapies. A growing number of athletes are turning to psychedelics
to help them recover from injuries obtained on the job. And this company which is founded by a
former athlete, is also backed by others like Tyson, has a clear plan to make a difference.
So you want to make sure you watch the video till the end so you don’t miss out
on their CEO sharing insights on the company and catalysts which could drive their share price up.
And do me a favour to drop a like on this video to spread its reach
and hit the bell so you never miss out on any of these gems from the channel..
YouTube also tells me only about 30% of my viewers are subscribed to the channel,
so if you are watching and not subscribed please consider subscribing with all notifications turned
so you get all video updates instantly.. There’s a link in the top pinned comment to my private
discord, where we call this gems there early and you join a strong community to help you on your
investment journey. So please check out the link and see for yourself. Thank you so much!
So let’s talk about Wesana Health Holdings Inc (OTCQB:WSNAF
CSE:WESA) it is now sitting at 54cents per share with a market cap of $11m.
Wesana hasn’t been spared by the current market crash as you can see it trending down
and close to all time lows. It is down 38% on the month but given some big FDA dates and milestones
in the pipeline, it could be seeing a turnaround soon. So certainly one to have on your watchlist.
Wesana Health ("Wesana") is an integrated life science company pioneering drug development,
clinical therapy, and remote patient monitoring solutions for psychedelic medicine in mental
health. Wesana helps people transcend barriers in mental health and performance.
So here’s what I feel is special with this company, which is that
Wesana’s drug development program looks to use a combination therapy to treat the symptoms
associated with Traumatic Brain Injury (“TBI”), such as depression and anxiety, and migraines.
By using psilocybin and cannabidiol (“CBD”), a combination therapy of compounds with demonstrated
effectiveness, Wesana’s lead drug candidate, SANA-013, is targeted to improve neuroplasticity
and neurogenesis while acting as an anti-neuroinflammatory,
to provide more sustained effects and benefit over time, which is some clever exciting stuff.
But before we go any further, lets hear from their CEO Daniel Carcillo on the journey of
the company and what investors can expect for 2022, which could drive its share price.
So some incredible ambition there to create a clinical network of health wellness facilities,
which is an awesome outlook. Wesana also recently Provided Strategic and Operational Updates.
They said Wesana was granted pre-IND meeting with FDA,
currently set for March 11, 2022 so we can expect the feedback on that imminently.
Wesana Clinics exhibited a record quarter of billings, new patient visits, telemedicine
utilization, overall patient appointments, and ketamine administrations. A New flagship clinic
is set to open in late Q1 2022 showcasing the service evolution of Wesana Clinics
and their Strategic restructuring program is to realize $1.1M in general corporate
overhead reduction and improve operational efficiencies which is all very exciting outlook.
The FDA granted their request for a pre-Investigational New
Drug (“IND”) meeting to discuss the novel therapy and proprietary protocol
of SANA-013 for the treatment of TBI-related major depressive disorder (“MDD”).
The outcome of the meeting will provide key development guidance in advance of IND clearance
and initiation of the Phase I clinical trial, currently anticipated to occur in late 2022.
Wesana Clinics saw a 40% increase in new patient volume and a 29% increase in new
appointments relative to the previous quarter. Additionally, the Clinics are expanding access to
mental health care through higher utilization of telemedicine appointments which accounted for 57%
of all appointments in the last quarter. The Company also announced a strategic
restructuring program as part of the next phase of the business to include a reorganization,
simplification of the Company’s operating structure and a reduction in the workforce
in order to streamline operations and drive efficiency,
which has reduced general corporate overhead annualized commitments by $1.1M.
Wesana Health Announced Positive Findings From Animal Study on Novel Depression Treatment
Protocol Combining Psilocybin and Cannabidiol. They announced positive results of an animal
study on a novel depression treatment protocol as the animal study, demonstrated considerable
and sustained improvement in depressive behaviors, which is very positive.
Even more interesting here is that, Wesana’s Provisional Patents Focus On Large Markets
With Considerable Unmet Needs including depression which has a projected market
size of $14.7Bn by 2025, Anxiety $7.4bn and migraine $7.8bn. So some huge numbers
which gives plenty of opportunities here for Wesana. And when you see the progress they’ve
made with one of their drug discoveries MAPS PBC findings which is entering its First FDS Phase
3 Trial For Psychedelic-Assisted Therapy, then you begin to appreciate the accelerated progress
they are making and what opportunities could lie ahead should it all be successful this 2022.
They have an experienced and diverse management team led by Daniel Carcillo who, for nine seasons,
played hockey professionally in the NHL, most famously with the Chicago Blackhawks playing
at the top of his game. Carcillo was forced to retire in 2015 at the young age of 30, due to a
condition known as post-concussion syndrome. And having not had much luck with traditional medical
Carcillo gave non-traditional medicine a chance which gave him some inspiration to create Wesana.
Wesana's scientific board is comprised of scientists
that already developed well-known drugs and brought them through
the entire commercialisation process to market, which is a strong place to be in.
Daniel is the largest personal shareholder of the company with a massive 22% shareholding, so
he has lots of skin in the game, which is what we like to see. Mike Tyson is also a major investor
in Wesana and he has spoken previously of his hopes to knock-out traumatic brain injuries with
psychedelic treatments and therapies. He’s often explained the impact of traumatic brain injury
he experienced, and the potential psychedelics offer in meaningful treatment of the conditions.
So in summary, Wesana is developing novel drugs with multi-billion dollar opportunity.
Their unique model of owning clinics is cash flowing generative
which is much needed to fund R&D from the psychiatrist-led clinics.
So some very very interesting and mindblowing prospects ahead for these penny stocks
but only consider getting in if the price is right for you and if you fully understand the
risks. This video is not financial advice, a buy or a sell recommendation, but is meant to bring
some new and exciting penny stocks to your attention for you to do your own research..
As always I would love to hear from you, so please let me know your thoughts on these top penny
stocks in the comments section below and what other penny stocks are catching your eyes lately.
And If you are new to my channel, please ensure to subscribe and hit the bell so you are notified
when I upload new videos. If you would like to see more videos like this, please check out this
video right here or this playlist right here to watch equally insightful content from the channel.
Thank you so much for being here and I look forward to have you in my next video. Thank you